Galapagos extends target discovery alliance with Cystic Fibrosis Foundation Therapeutics
Galapagos NV announced the extension of the target discovery alliance between its service division BioFocus DPI and cystic fibrosis Foundation Therapeutics, Inc. (CFFT), the drug discovery and development affiliate of the Cystic Fibrosis Foundation. This 15-month extension exceeds EUR800,000 in research fees and builds further on the alliance initiated in April 2005. BioFocus DPI is applying its SilenceSelect adenoviral library and expertise in assay design to discover novel drug targets for the development of new cystic fibrosis therapies.
"The project to discover novel targets for cystic fibrosis is proceeding very well, and we are therefore pleased and proud that Cystic Fibrosis Foundation Therapeutics has extended the alliance. This will enable BioFocus DPI to deliver validated targets as the basis for the development of new medicines," said Onno van de Stolpe, Chief Executive Officer of Galapagos. "It is particularly gratifying that our target discovery engine is being applied to the unmet medical needs addressed by patient foundations such as the Cystic Fibrosis Foundation."
Other news from the department business & finance
